As surgeons and medical professionals continually strive to stay abreast of advancements within and tangential to their field, the evolution of medicine has brought groundbreaking techniques to the fore, particularly in oncology. One such advancement, the “liquid biopsy”, is garnering significant interest due to its potential to revolutionize the way we understand and treat colorectal cancer (CRC). This article delves into the promise of “liquid biopsy”, its mechanisms, and how it could shape the future of CRC management.
Understanding “Liquid Biopsy”
A “liquid biopsy” is a minimally invasive technique that involves the analysis of biomarkers in a sample of a patient’s blood to provide information about a cancerous tumor. Unlike traditional biopsy—which requires the removal of tissue from a primary tumor or metastatic site for examination—”liquid biopsy” can detect and analyze circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or exosomes that are shed by the tumor into the bloodstream. This dynamic method not only reflects the current state of cancer within the body but also has the potential to transform patient prognosis and personalization of therapy.
Circulating Tumor Cells (CTCs)
CTCs are cancer cells that have detached from the original tumor and are traveling through the bloodstream. Research has shown that CTCs have significant prognostic value, as their presence, quantity, and characteristics can offer insights into the aggressiveness of the cancer, the likelihood of metastasis, and patient survival rates. CTC analysis in colorectal cancer provides valuable information for treatment decisions and can be performed before, during, or after treatment to monitor the disease’s progression or response to therapy.
Circulating Tumor DNA (ctDNA)
ctDNA represents fragments of DNA shed from a tumor into the bloodstream. By analyzing ctDNA, clinicians can detect genetic mutations that drive cancer growth, monitor mutation patterns over time, and identify emerging resistance to targeted therapies. In colorectal cancer, ctDNA offers a “real-time” perspective of the tumor’s genetic landscape, aiding in the early detection of relapses and facilitating the modification of treatment regimens according to evolving tumor biology.
Exosomes
Exosomes are tiny vesicles released by cells, including cancer cells, into bodily fluids. They carry a cargo of proteins, lipids, and nucleic acids that reflect the characteristics of their cell of origin. In the context of oncology, exosomes derived from cancer cells can provide insights into the molecular makeup of tumors as well as the mechanisms by which cancer evades the immune system or responds to treatment.
Potential and Challenges
“Liquid biopsy” has the potential to transform colorectal cancer care by allowing for earlier detection, real-time monitoring, and individualized treatment strategies. However, challenges remain in achieving optimal sensitivity and specificity for detecting tumor-derived material in the bloodstream, as well as in standardizing and interpreting results. Despite these obstacles, the continual improvements of “liquid biopsy” technology could one day minimize the need for invasive procedures and offer patients with CRC non-invasive options for diagnosis and monitoring.
Implications for Surgery in CRC
The integration of “liquid biopsy” into clinical practice has the potential to enhance surgical decision-making. While surgical resection remains the cornerstone of curative treatment for localized colorectal cancer, the additional molecular data provided by “liquid biopsies” can aid in preoperative planning, assessing the likelihood of metastatic spread, and guiding adjuvant therapy to reduce the risk of recurrence.
Conclusion
In conclusion, “liquid biopsy” serves as a versatile tool that holds significant promise for improving the management of colorectal cancer. By offering a non-invasive, real-time snapshot of the tumor’s characteristics, “liquid biopsy” can potentially lead to more tailored and effective treatments, improving prognosis and outcomes for CRC patients. As research continues and technology matures, the role of “liquid biopsy” in clinical practice is expected to grow, providing exciting prospects for the field of oncology and beyond.
DOI: 10.21614/chirurgia.114.2.162
References:
1. Scripcariu, V., Scripcariu, D.-V., Filip, B., Gavrilescu, M.-M., Muşină, A.-M., & Volovăţ, C. (2019). “Liquid Biopsy” – Is it a Feasible Option in Colorectal Cancer? Chirurgia (Bucharest, Romania: 1990), 114(2), 162–166. https://doi.org/10.21614/chirurgia.114.2.162
2. Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10(8), 472–484. https://doi.org/10.1038/nrclinonc.2013.110
3. Alix-Panabières, C., & Pantel, K. (2016). Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discovery, 6(5), 479–491. https://doi.org/10.1158/2159-8290.CD-15-1483
4. Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019). Current and future perspectives of liquid biopsies in genomics-driven oncology. Nature Reviews Genetics, 20(2), 71–88. https://doi.org/10.1038/s41576-018-0071-5
5. Pantel, K., & Alix-Panabières, C. (2019). Liquid biopsy and minimal residual disease – latest advances and implications for cure. Nature Reviews Clinical Oncology, 16(7), 409–424. https://doi.org/10.1038/s41571-019-0187-3
Keywords
1. Liquid biopsy colorectal cancer
2. Circulating tumor DNA
3. Circulating tumor cells
4. Colorectal cancer management
5. Exosomes cancer diagnosis